Skip to main content
    V

    vTv Therapeutics Inc (VTVT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $27.52
    -0.71 (-2.52%)

    Market Cap: $111.62M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    59%(22/37)
    Avg Surprise
    -132.46%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.18
    Range$-1.29 - $-1.06
    4 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.04-13.0%
    60d ago$-1.12-5.5%
    30d ago$-1.180.0%
    7d ago$-1.180.0%
    Current$-1.18
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.26
    Range$-2.24 - $0.65
    4 analysts
    Revenue Consensus
    $19M
    Range$-10180000 - $27M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.26---
    Sep 26EST
    		-$-1.18---
    Jun 26
    Reported Aug 6
    		$-1.05$-0.75-40.00%Miss-14.1%
    Mar 26
    Reported May 13
    		$1.65$0.21+685.71%Beat+314.3%
    Dec 25
    Reported Mar 10
    		$-0.58$-1.09+46.69%Beat-5.1%
    Sep 25
    Reported Nov 6
    		$-1.08$-0.98-10.20%Miss-22.7%
    Jun 25
    Reported Aug 12
    		$-0.92$-0.82-12.20%Miss-13.7%
    Mar 25
    Reported May 15
    		$-0.77$-0.73-5.48%Miss+34.5%
    Dec 24
    Reported Mar 20
    		$-0.55$-0.87+36.55%Beat+66.9%
    Sep 24
    Reported Nov 12
    		$-0.88N/A+75.56%Beat+72.5%
    Jun 24
    Reported Aug 8
    		$-0.81N/AN/ABeat-1055.6%
    Mar 24
    Reported May 9
    		$-1.17N/AN/ABeat-1857.8%
    Dec 23
    Reported Mar 13
    		$-1.67$-0.07-2285.71%Miss+30.4%
    Sep 23
    Reported Nov 9
    		$-3.20$-0.08-3900.00%Miss-60.0%
    Jun 23
    Reported Aug 11
    		$-0.07$-0.07+0.00%Beat+95.6%
    Mar 23
    Reported May 11
    		$-0.06$-0.09+33.33%Beat+98.5%
    Dec 22
    Reported Mar 6
    		$-2.40$-2.40+0.00%Beat-2081.8%
    Sep 22
    Reported Nov 10
    		$-2.00$-1.80-11.11%Miss-150.0%
    Jun 22
    Reported Aug 15
    		$-1.60N/A+60.00%Beat-300.0%
    Mar 22
    Reported May 12
    		$-4.00$-3.20-25.00%Miss-25.0%
    Dec 21
    Reported Mar 29
    		$-0.11$-0.07-57.14%Miss-650.0%
    Sep 21
    Reported Nov 9
    		$-0.80N/A+71.43%Beat+33.3%
    Jun 21
    Reported Aug 4
    		$-0.40N/A+85.71%Beat+85.7%
    Mar 21
    Reported May 5
    		$-3.20$-2.40-33.33%Miss+27.3%
    Dec 20
    Reported Feb 24
    		$0.02N/A+140.00%Beat+115.4%
    Sep 20
    Reported Nov 5
    		$-1.20N/A+71.43%Beat+83.8%
    Jun 20
    Reported Aug 3
    		$-2.80$-3.80+26.32%Beat+22.2%
    Mar 20
    Reported May 7
    		$-4.40$-4.00-10.00%Miss-4788.9%
    Dec 19
    Reported Feb 20
    		$-0.13$-0.09-44.44%Miss+93.5%
    Sep 19
    Reported Oct 30
    		$-7.42$-6.40-15.94%Miss-209.2%
    Jun 19
    Reported Jul 31
    		$-3.60$-6.40+43.75%Beat+71.0%
    Mar 19
    Reported May 1
    		$-0.09N/A+62.50%Beat+99.3%
    Dec 18
    Reported Feb 27
    		$-2.00N/A+54.55%Beat+88.6%
    Sep 18
    Reported Nov 8
    		$-2.40$-4.80+50.00%Beat+84.2%
    Jun 18
    Reported Aug 3
    		$-12.40$-16.00+22.50%Beat+24.4%
    Mar 18
    Reported May 15
    		$-12.00$-16.40+26.83%Beat+31.8%
    Dec 17
    Reported Feb 27
    		$-17.60$-16.60-6.02%Miss-4090.5%
    Sep 17
    Reported Nov 1
    		$-15.20$-15.80+3.80%Beat-
    Jun 17
    Reported Aug 2
    		$-16.40$-18.00+8.89%Beat-
    Mar 17
    Reported May 3
    		$-17.60$-17.60+0.00%Beat-
    Dec 16
    Reported Feb 27
    		$-0.42$-0.28-50.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio-25.96EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-12.90%Operating Margin-25.10%
    ROE-15.80%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio12.48xQuick Ratio12.48x
    Trading Statistics
    Beta0.21Avg Volume37.71K
    52-Week High$44.0052-Week Low$19.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$30.13
    SMA 20$30.49
    SMA 50$31.78
    SMA 200$34.27
    EMA 10$29.73
    EMA 20$30.38
    EMA 50$31.39
    EMA 200$31.76

    MACD

    Line: -0.75Signal: -0.53Hist: -0.22

    ADX

    ADX: 11.1+DI: 14.1-DI: 25.8

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$31.75

    Bollinger Bands

    Upper Band$32.59
    Lower Band$28.38
    %B Position1380%(Upper)
    Band Width-0.21

    RSI (14-Day)

    Neutral
    34.2

    Momentum Oscillators

    Stoch %K13.9
    Stoch %D27.7
    Williams %R-99.4
    ROC (10d)-10.8%
    Momentum-3.32
    CCI (20d)-302.4
    MFI (14d)42.6

    Volatility Measures

    ATR (14d)$1.45(5.3%)
    StdDev (20d)1.05
    Hist Vol45.2%(High)

    Volume Flow

    VWAP$27.96
    OBV-11.4K
    AD Line-430.6K
    CMF (20d)-0.256

    Volume Metrics

    Avg Vol (20d)34.6K
    Vol Ratio0.6x
    VWMA (20d)$30.50

    Pivot Points

    R3$33.69
    R2$32.45
    R1$30.34
    Pivot Point$29.11
    S1$27.00
    S2$25.76
    S3$23.65

    Advanced Oscillators

    TSI-16.31
    Ultimate Osc33.9
    KST-54.96

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$36.84M$-24,000$0$0$0$17,000$0$0$1.00M$-9,000$0
    Cost of Revenue$0$0$2,000$0$0$0$22,000$0$0$0$23,000$0
    Gross Profit$0$36.84M$-2,000$0$0$0$17,000$0$0$1.00M$-23,000$0
    Operating Expenses$13.93M$13.58M$7.88M$10.70M$7.72M$6.50M$4.91M$6.51M$7.16M$6.63M$4.71M$5.37M
    R&D$8.77M$8.98M$3.91M$7.02M$4.10M$2.83M$2.23M$3.22M$3.44M$2.65M$2.14M$2.82M
    SG&A$5.16M$4.60M$3.98M$3.68M$3.62M$3.67M$2.67M$3.28M$3.72M$3.98M$2.57M$2.54M
    Operating Income$-13,930,000$23.26M$-7,885,000$-10,699,000$-7,721,000$-6,503,000$-4,892,000$-6,506,000$-7,155,000$-5,627,000$-4,707,000$-5,368,000
    Interest Income$812,000$838,000$865,000$399,000$275,000$331,000$429,000$504,000$553,000$79,000$88,000$131,000
    Interest Expense$0$0$1,000$5,000$0$0$0$0$0$292,000$0$4,000
    Income Before Tax$-13,054,000$24.13M$-7,138,000$-10,345,000$-7,380,000$-6,217,000$-4,437,000$-5,840,000$-6,409,000$-5,919,000$-4,441,000$-8,540,000
    Income Tax Expense$0$0$-2,459,000$0$0$0$0$0$0$100,000$0$0
    Net Income$-13,054,000$24.13M$-7,138,000$-10,345,000$-7,380,000$-6,217,000$-4,437,000$-5,840,000$-6,409,000$-6,019,000$-4,441,000$-8,540,000
    EBITDA$-13,865,000$23.30M$-7,135,000$-10,737,000$-7,652,000$-6,539,000$-4,844,000$-6,322,000$-6,939,000$-5,976,000$-4,499,000$-8,645,000
    EBIT$-13,866,000$23.30M$-7,137,000$-10,739,000$-7,655,000$-6,548,000$-4,866,000$-6,344,000$-6,962,000$-5,998,000$-4,522,000$-8,667,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VTVT

    News

    Three parties report shared voting power over vTv Therapeutics (VTVT) shares in a passive stake amendment.

    Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an amended passive investment disclosure (SCHEDULE 13G/A) for vTv Therapeutics Inc....

    Stock Titan•10/8/26•Neutral

    ETFs Investing in vTv Therapeutics, Inc. Class A Stocks

    This article lists ETFs that invest in vTv Therapeutics, Inc. Class A stocks, sorted by market value. It highlights two specific ETFs: iShares Microcap ETF (IWC) and Invesco NASDAQ Future Gen 200 ETF (QQQS)...

    TradingView•8/23/26•Neutral

    vTv Therapeutics (VTVT) Stock Rises Despite Widening Losses And Zero Revenue

    vTv Therapeutics (VTVT) stock rose 2.2% despite reporting widening losses and zero revenue in Q2 2026. The company's net loss roughly doubled year-on-year to US$13.054m...

    Sahm•8/9/26•Somewhat-Bearish

    vTv Therapeutics Inc.: vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

    vTv Therapeutics Inc. has reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company expects to complete enrollment in its Phase 3 CATT1 trial...

    FinanzNachrichten.de•8/6/26•Bullish

    vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

    vTv Therapeutics (Nasdaq: VTVT) announced its second-quarter 2026 financial results, highlighting that enrollment for its Phase 3 CATT1 trial for cadisegliatin, an oral therapy for type 1 diabetes...

    GlobeNewswire•8/6/26•Bullish

    VTVT Valuation and Fair Value

    P/E
    -26.0x
    PEG
    0.0x
    P/B
    4.3x
    See GNG's fair value

    VTVT Profitability: Margins, ROIC and FCF

    Operating margin
    -25.1%
    Net margin
    -12.9%
    ROE
    -15.8%

    VTVT Competitors

    CompanyTicker
    NRX Pharmaceuticals IncNRXP
    Cellectis SACLLS
    TuHURA Biosciences IncHURA
    Foghorn Therapeutics IncFHTX
    Minerva Neurosciences IncNERV
    Tonix Pharmaceuticals Holding CorpTNXP
    Cumberland Pharmaceuticals IncCPIX
    LENZ Therapeutics IncLENZ

    Sector: Healthcare

    VTVT Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    0
    Buy
    7
    Hold
    0
    Sell
    0
    Strong Sell
    0

    VTVT Bull Case vs Bear Case

    Bull case

    • 100.0% of VTVT's analyst ratings are Buy or Strong Buy.

    Bear case

    • VTVT has a -12.9% net profit margin.

    VTVT Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    97.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.18
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 1 down

    Frequently Asked Questions About VTVT

    Does VTVT pay dividends?

    vTv Therapeutics Inc (VTVT) does not currently pay a regular dividend.

    What is VTVT's market cap?

    vTv Therapeutics Inc (VTVT) has a market capitalization of $111.62M with a current stock price of $27.52.

    Related stocks

    Sector: Healthcare

    All stocks starting with V

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In